ArticleMedical oncology (Northwood, London, England)2025
Protective effects of valencene, a natural sesquiterpene, against benzo(a)pyrene-induced lung cancer in Swiss albino mice.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains a leading cause of cancer-related mortality worldwide, necessitating the development of novel chemopreventive and therapeutic agents. Valencene, a natural sesquiterpene, has shown potential bioactive properties, but its efficacy against benzo(a)pyrene (B(a)P)-induced lung carcinogenesis remains underexplored. This study investigated the protective and therapeutic effects of Valencene on B(a)P-induced lung cancer in mice, focusing on its impact on body weight, lung weight, oxidative stress biomarkers, serum marker enzymes, and histopathological alterations. Mice were divided into four groups: normal control, B(a)P-induced disease control, Valencene pre-treatment (B(a)P + Valencene), and Valencene post-treatment [B(a)P followed by Valencene]. Body and lung weights were recorded, while oxidative stress markers [superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx)] and serum enzymes (adenosine deaminase (ADA), aryl hydrocarbon hydroxylase (AHH) were analyzed. Histopathological examination assessed lung tissue integrity. B(a)P induction caused significant body weight loss (15.7 ± 0.25 g vs. control 33.61 ± 0.03 g, p < 0.01) and increased lung weight (360 ± 1.39 mg vs. control 286.33 ± 1.93 mg, p < 0.01), indicating cancer-associated metabolic and pathological changes. Valencene pre-treatment significantly attenuated these effects (body weight: 26.33 ± 0.05 g; lung weight: 303.16 ± 5.05 mg, p < 0.01), whereas post-treatment showed moderate recovery. Oxidative stress biomarkers (SOD, CAT, GPx) were significantly restored by Valencene (p < 0.001), with pre-treatment exhibiting superior efficacy. Additionally, Valencene normalized serum ADA and AHH levels, suggesting anti-carcinogenic activity. Histopathological analysis confirmed that pre-treatment preserved lung architecture, while post-treatment partially reversed carcinogenic damage. Valencene demonstrates potent chemopreventive and therapeutic effects against B(a)P-induced lung cancer, primarily by mitigating oxidative stress, reducing tumor burden, and preserving tissue integrity. Pre-treatment was more effective than post-treatment, highlighting its potential as a prophylactic agent. These findings support further exploration of Valencene as a complementary strategy in lung cancer management.
Indexed as
Identifiers
40736625What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.